Bordetella pertussis B1917
PreclinicalBiologic
Bordetella pertussis B1917 is one of 5 biologic programs targeting Pertussis. It is currently in Preclinical.
2
Indications
2
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
5 competitors in Antibiotic Therapy
#DrugCompanyPhaseTrials
1Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 1
Rifampicin
Boehringer IngelheimPreclinical
Azithromycin Pill
RRambam Health Care Campus
Preclinical
Bordetella pertussis B1917
UUniversity of Southampton
Preclinical
Antibiotic Withdrawal
CCentre Hospitalier Universitaire, Amiens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bordetella pertussis B1917. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Southampton